cancer

Karista invests in MyPL increasing its financing to €1.8m & accelerating its development

Show more

Domain Therapeutics launches Phase 1-enabling studies on proprietary EP4 receptor antagonist program in cancer immunotherapy

Show more

Domain Therapeutics enters into a new collaboration agreement with Pfizer Inc. to profile signaling pathways of GPCRs across multiple diseases

Show more

Domain Therapeutics receives development milestone payment from Merck KGaA, Darmstadt, Germany, for collaboration on adenosine receptor antagonists

Show more